Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1985 Oct 1;231(1):59–63. doi: 10.1042/bj2310059

Arginine residues are critical for the heparin-cofactor activity of antithrombin III.

A M Jorgensen, C L Borders Jr, W W Fish
PMCID: PMC1152703  PMID: 4062892

Abstract

A dilution/quench technique was used to monitor the time course of chemical modification on the heparin-cofactor (a) and progressive thrombin-inhibitory (b) activities of human antithrombin III. Treatment of antithrombin III (AT III) with 2,4,6-trinitrobenzenesulphonate at pH 8.3 and 25 degrees C leads to the loss of (a) at 60-fold more rapid rate than the loss of (b). This is consistent with previous reports [Rosenberg & Damus (1973) J. Biol. Chem. 248, 6490-6505; Pecon & Blackburn (1984) J. Biol. Chem. 259, 935-938] that lysine residues are involved in the binding of heparin to AT III, but not in thrombin binding. Treatment of AT III with phenylglyoxal at pH 8.3 and 25 degrees C again leads to a more rapid loss of (a) than of (b), with the loss of the former proceeding at a 4-fold faster rate. The presence of heparin during modification with phenylglyoxal significantly decreases the rate of loss of (a). Full loss of (a) correlates with the modification of seven arginine residues per inhibitor molecule, whereas loss of (b) does not commence until approximately four arginine residues are modified and is complete upon the modification of approximately eleven arginine residues per inhibitor molecule. This suggests that (the) arginine residue(s) in AT III are involved in the binding of heparin in addition to the known role of Arg-393 at the thrombin-recognition site [Rosenberg & Damus (1973) J. Biol. Chem. 248, 6490-6505; Jörnvall, Fish & Björk (1979) FEBS Lett. 106, 358-362].

Full text

PDF
57

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjerrum P. J., Wieth J. O., Borders C. L., Jr Selective phenylglyoxalation of functionally essential arginyl residues in the erythrocyte anion transport protein. J Gen Physiol. 1983 Apr;81(4):453–484. doi: 10.1085/jgp.81.4.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Björk I., Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem. 1982 Oct 29;48(3):161–182. doi: 10.1007/BF00421226. [DOI] [PubMed] [Google Scholar]
  3. Björk I., Nordling K. Evidence by chemical modification for the involvement of one or more tryptophanyl residues of bovine antithrombin in the binding of high-affinity heparin. Eur J Biochem. 1979 Dec 17;102(2):497–502. doi: 10.1111/j.1432-1033.1979.tb04265.x. [DOI] [PubMed] [Google Scholar]
  4. Blackburn M. N., Sibley C. C. The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. J Biol Chem. 1980 Feb 10;255(3):824–826. [PubMed] [Google Scholar]
  5. Blackburn M. N., Smith R. L., Carson J., Sibley C. C. The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence. J Biol Chem. 1984 Jan 25;259(2):939–941. [PubMed] [Google Scholar]
  6. Blombäck M., Blombäck B., Olsson P., Svendsen L. The assay of antithrombin using a synthetic chromogenic substrate for thrombin. Thromb Res. 1974 Nov;5(5):621–632. doi: 10.1016/0049-3848(74)90052-8. [DOI] [PubMed] [Google Scholar]
  7. Bock S. C., Wion K. L., Vehar G. A., Lawn R. M. Cloning and expression of the cDNA for human antithrombin III. Nucleic Acids Res. 1982 Dec 20;10(24):8113–8125. doi: 10.1093/nar/10.24.8113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Borders C. L., Jr, Patrick S. L., Davis T. L., Mézes P. S., Viswanatha T. Inactivation of beta-lactamase I from B. cereus 569/H with phenylglyoxal, an arginine-selective reagent. Biochem Biophys Res Commun. 1982 Nov 16;109(1):242–249. doi: 10.1016/0006-291x(82)91591-1. [DOI] [PubMed] [Google Scholar]
  9. Borders C. L., Jr, Riordan J. F. An essential arginyl residue at the nucleotide binding site of creatine kinase. Biochemistry. 1975 Oct 21;14(21):4699–4704. doi: 10.1021/bi00692a021. [DOI] [PubMed] [Google Scholar]
  10. Chandra T., Stackhouse R., Kidd V. J., Woo S. L. Isolation and sequence characterization of a cDNA clone of human antithrombin III. Proc Natl Acad Sci U S A. 1983 Apr;80(7):1845–1848. doi: 10.1073/pnas.80.7.1845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Choay J., Petitou M., Lormeau J. C., Sinaÿ P., Casu B., Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983 Oct 31;116(2):492–499. doi: 10.1016/0006-291x(83)90550-8. [DOI] [PubMed] [Google Scholar]
  12. Einarsson R., Andersson L. O. Binding of heparin to human antithrombin III as studied by measurements of tryptophan fluorescence. Biochim Biophys Acta. 1977 Jan 25;490(1):104–111. doi: 10.1016/0005-2795(77)90110-6. [DOI] [PubMed] [Google Scholar]
  13. Ferguson W. S., Finlay T. H. Localization of the disulfide bond in human antithrombin III required for heparin-accelerated thrombin inactivation. Arch Biochem Biophys. 1983 Feb 15;221(1):304–307. doi: 10.1016/0003-9861(83)90147-9. [DOI] [PubMed] [Google Scholar]
  14. George A. L., Jr, Borders C. L., Jr Chemical modification of histidyl and lysyl residues in yeast enolase. Biochim Biophys Acta. 1979 Jul 11;569(1):63–69. doi: 10.1016/0005-2744(79)90081-0. [DOI] [PubMed] [Google Scholar]
  15. Goldfarb A. R. A kinetic study of the reactions of amino acids and peptides with trinitrobenzenesulfonic acid. Biochemistry. 1966 Aug;5(8):2570–2574. doi: 10.1021/bi00872a013. [DOI] [PubMed] [Google Scholar]
  16. Jörnvall H., Fish W. W., Björk I. The thrombin cleavage site in bovine antithrombin. FEBS Lett. 1979 Oct 15;106(2):358–362. doi: 10.1016/0014-5793(79)80532-3. [DOI] [PubMed] [Google Scholar]
  17. Koide T., Odani S., Takahashi K., Ono T., Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984 Jan;81(2):289–293. doi: 10.1073/pnas.81.2.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  19. Lindahl U., Bäckström G., Hök M., Thunberg L., Fransson L. A., Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci U S A. 1979 Jul;76(7):3198–3202. doi: 10.1073/pnas.76.7.3198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Longas M. O., Ferguson W. S., Finlay T. H. A disulfide bond in antithrombin is required for heparin-accelerated thrombin inactivation. J Biol Chem. 1980 Apr 25;255(8):3436–3441. [PubMed] [Google Scholar]
  21. Odegard O. R., Lie M., Abildgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res. 1975 Apr;6(4):287–294. doi: 10.1016/0049-3848(75)90078-x. [DOI] [PubMed] [Google Scholar]
  22. Olson S. T., Srinivasan K. R., Björk I., Shore J. D. Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction. J Biol Chem. 1981 Nov 10;256(21):11073–11079. [PubMed] [Google Scholar]
  23. Owen W. G. Evidence for the formation of an ester between thrombin and heparin cofactor. Biochim Biophys Acta. 1975 Oct 20;405(2):380–387. doi: 10.1016/0005-2795(75)90103-8. [DOI] [PubMed] [Google Scholar]
  24. Pecon J. M., Blackburn M. N. Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III. J Biol Chem. 1984 Jan 25;259(2):935–938. [PubMed] [Google Scholar]
  25. Prochownik E. V., Markham A. F., Orkin S. H. Isolation of a cDNA clone for human antithrombin III. J Biol Chem. 1983 Jul 10;258(13):8389–8394. [PubMed] [Google Scholar]
  26. Riordan J. F. Arginyl residues and anion binding sites in proteins. Mol Cell Biochem. 1979 Jul 31;26(2):71–92. doi: 10.1007/BF00232886. [DOI] [PubMed] [Google Scholar]
  27. Riordan J. F. Functional arginyl residues in carboxypeptidase A. Modification with butanedione. Biochemistry. 1973 Sep 25;12(20):3915–3923. doi: 10.1021/bi00744a020. [DOI] [PubMed] [Google Scholar]
  28. Riordan J. F., McElvany K. D., Borders C. L., Jr Arginyl residues: anion recognition sites in enzymes. Science. 1977 Mar 4;195(4281):884–886. doi: 10.1126/science.190679. [DOI] [PubMed] [Google Scholar]
  29. Rosenberg R. D. Chemistry of the hemostatic mechanism and its relationship to the action of heparin. Fed Proc. 1977 Jan;36(1):10–18. [PubMed] [Google Scholar]
  30. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  31. Rosenberg R. D., Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci U S A. 1979 Mar;76(3):1218–1222. doi: 10.1073/pnas.76.3.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Takahashi K. The reaction of phenylglyoxal with arginine residues in proteins. J Biol Chem. 1968 Dec 10;243(23):6171–6179. [PubMed] [Google Scholar]
  33. Takahashi K. The reactions of phenylglyoxal and related reagents with amino acids. J Biochem. 1977 Feb;81(2):395–402. doi: 10.1093/oxfordjournals.jbchem.a131471. [DOI] [PubMed] [Google Scholar]
  34. Villaneuva G. B., Danishefsky I. Evidence for a heparin-induced conformational change on antithrombin III. Biochem Biophys Res Commun. 1977 Jan 24;74(2):803–809. doi: 10.1016/0006-291x(77)90374-6. [DOI] [PubMed] [Google Scholar]
  35. Villaneuva G. B., Perret V., Danishefsky I. Tryptophan residue at the heparin binding site in antithrombin III. Arch Biochem Biophys. 1980 Aug;203(1):453–457. doi: 10.1016/0003-9861(80)90198-8. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES